Table 2.
Drug delivery system for liver fibrosis therapy.
| Strategy | Drug | Particle size | Targeting ligand | Polymer/Formulation | Reference |
|---|---|---|---|---|---|
| Hepatocyte targeting | Oxymatrine | – | RGD peptide | Liposomes | Chai et al. |
| siRNA against apoB | <200 nm | – | PEI-pullulan/siRNA complex | Kang et al. | |
| Quercetin | – | Galactosylate | Liposomes | Mandal et al. | |
| HSC targeting | siRNA against gp46 | 153.9 nm | Vitamin A | Liposomes | Sato et al. |
| Vismodegib | 80 nm | cRGDyK | Lipoid S100 and mPEG2000-DSPE/Liposome | Li et al. | |
| Antisense oligodeoxynucleotide against collagen I | 115 nm | Retinol | PEI/Complex of PEI/ASO | Zhang et al. | |
| Silibinin and siCOL1α1 | 151 nm | Vitamin A | PLGA-PSPE-PEG/Micelles | Qiao et al. | |
| siRNA against TGF-β1 | – | Galactosylate | Galactosylated PEG | Zhu et al. | |
| IFN-γ | <100 nm | Cyclic peptide | mPEG2000-DSPE/Liposome | Li et al. | |
| Silibinin | 40 nm | Hyaluronic acid (HA) | Lipoid E80/DOCA-Na/Micelles | Li et al. | |
| – | – | PDGFR binding peptide (C * SRNLIDC * ) | Peptide-modified albumin | Beljaars et al. | |
| Hepatocyte growth factor (HGF) | 50–100 nm | – | HGF incorporated chitosan nanoparticle | Pulavendran et al. | |
| siRNA against TGF-β1 | 100 nm | Hyaluronic acid (HA) | siRNA/(PEI-SS)-g-HA complex targeting HSC | Park et al. | |
| – | – | Nerve growth factor peptide (NGFp) | Ad serotype 5-derived wild-type vector | Reetz et al. | |
| Kupffer cell targeting | siRNA against migration inhibitory factor | 139.1 nm | Glucan | BG34–10-Re-I/siRNA nanoparticle | Zhang et al. |
| 350.5 nm | Phospholipid serine | Ac-Dex nanoparticle | Wang et al. |